Roche has acquired the Austrian biotech company Dutalys, a specialist in the discovery and development of bi-specific antibodies, for a total sum of $489 million. Dutalys was founded in April 2010 with seed financing from Austria Wirtschaftsservice. Roche will make an upfront cash payment of $133.75 million and additional payments of up to $355 million if certain predetermined milestones are reached. The deal strengthens Roche’s leading position in the development of therapeutic antibodies.

Bi-specific antibody therapy is an emerging technology based on artificial proteins composed of fragments of two different monoclonal antibodies, which can bind in two different places in a disease pathway. Dutalys’ proprietary technology is able to create fully human bi-specific antibodies and is still at an early stage in the drug development process. According to Roche, it could provide novel molecules for several therapeutic areas.


Please enter your comment!
Please enter your name here